GPT and Hyperglycemia: The most frequent grade 3–4 adverse events in the buparlisib versus placebo group were elevated alanine aminotransferase (63 (22%) of 288 patients vs. four (3%) of 140), elevated aspartate aminotransferase (51 (18%) vs. four (3%)), hyperglycemia (35 (12%) vs. none).